|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Conroy T, Desseigne F, Ychou M, Bouche O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Satoi S, Yamaue H, Kato K, Takahashi S,
Hirono S, Takeda S, Eguchi H, Sho M, Wada K, Shinchi H, et al: Role
of adjuvant surgery for patients with initially unresectable
pancreatic cancer with a long-term favorable response to
non-surgical anti-cancer treatments: Results of a project study for
pancreatic surgery by the Japanese society of
hepato-biliary-pancreatic surgery. J Hepatobiliary Pancreat Sci.
20:590–600. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
National Comprehensive Cancer Network, .
NCCN Clinical practice guidelines in oncology: pancreatic
adenocarcinoma. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdfAugust
29–2023
|
|
7
|
Zhou Y, Liao S, You J and Wu H: Conversion
surgery for initially unresectable pancreatic ductal adenocarcinoma
following induction therapy: A systematic review of the published
literature. Updates Surg. 74:43–53. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tanaka M, Heckler M, Mihaljevic AL, Sun H,
Klaiber U, Heger U, Buchler MW and Hackert T: CT response of
primary tumor and CA19-9 predict resectability of metastasized
pancreatic cancer after FOLFIRINOX. Eur J Surg Oncol. 45:1453–1459.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang M, Zhu P, Chen Z and Yang L:
Conversion therapy, palliative chemotherapy and surgery, which of
these is the best treatment for locally advanced and advanced
pancreatic cancer? Anticancer Drugs. 33:e686–e691. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yanagimoto H, Satoi S, Yamamoto T, Yamaki
S, Hirooka S, Kotsuka M, Ryota H, Ishida M, Matsui Y and Sekimoto
M: Benefits of conversion surgery after multimodal treatment for
unresectable pancreatic ductal adenocarcinoma. Cancers (Basel).
12:14282020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ushida Y, Inoue Y, Oba A, Mie T, Ito H,
Ono Y, Sato T, Ozak a, Sasaki T, Saiura A, et al: Optimizing
indications for conversion surgery based on analysis of 454
consecutive Japanese cases with unresectable pancreatic cancer who
received modified FOLFIRINOX or gemcitabine plus nab-paclitaxel: A
single-center retrospective study. Ann Surg Oncol. 29:5038–5050.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takano N, Yamada S, Sonohara F, Inokawa Y,
Takami H, Hayashi M, Koike M, Fujii T and Kodera Y: The impact of
early tumor shrinkage on conversion surgery and the survival in
patients with unresectable locally advanced pancreatic cancer. Surg
Today. 51:1099–1107. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee M, Kang JS, Kim H, Kwon W, Lee SH, Ryu
JK, Kim YT, Oh DY, Chie EK and Jang JY: Impact of conversion
surgery on survival in locally advanced pancreatic cancer patients
treated with FOLFIRINOX chemotherapy. J Hepatobiliary Pancreat Sci.
30:111–121. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mataki Y, Kurahara H, Idichi T, Tanoue K,
Hozaka Y, Kawasaki Y, Iino S, Maemura K, Shinchi H and Ohtsuka T:
Clinical benefits of conversion surgery for unresectable pancreatic
ductal adenocarcinoma: A single-institution, retrospective
analysis. Cancers (Basel). 13:10572021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kokumai T, Aoki S, Mizuma M, Maeda S,
Ohtsuka H, Nakagawa K, Morikawa T, Motoi F, Kamei T and Unno M:
Prognostic value of an inflammation-based nutritional score for
patients with initially unresectable pancreatic adenocarcinoma
undergoing conversion surgery following chemo-/radiotherapy. Surg
Today. 51:1682–1693. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tsuchiya N, Matsuyama R, Murakami T,
Yabushita Y, Sawada Y, Kumamoto T and Endo I: Role of conversion
surgery for unresectable pancreatic cancer after long-term
chemotherapy. World J Surg. 44:2752–2760. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Japan Pancreas Society, . Classification
of Pancreatic Carcinoma (4th English Edition). Kanehara & Co.;
Tokyo, Japan: 2017, http://www.suizou.org/pdf/Classification_of_Pancreatic_Carcinoma_4th_Engl_ed.pdfAugust
30–2023
|
|
18
|
Kanda M, Fujii T, Kodera Y, Nagai S,
Takeda S and Nakao A: Nutritional predictors of postoperative
outcome in pancreatic cancer. Br J Surg. 98:268–274. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Toiyama Y, Miki C, Inoue Y, Tanaka K,
Mohri Y and Kusunoki M: Evaluation of an inflammation-based
prognostic score for the identification of patients requiring
postoperative adjuvant chemotherapy for stage II colorectal cancer.
Exp Ther Med. 2:95–101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Simon R and Makuch RW: A non-parametric
graphical representation of the relationship between survival and
the occurrence of an event: Application to responder versus
non-responder bias. Stat Med. 3:35–44. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schultz LR, Peterson EL and Breslau N:
Graphing survival curve estimates for time-dependent covariates.
Int J Methods Psychiatr Res. 11:68–74. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cao J, Luo F, Zeng K, Ma W, Lu F, Huang Y,
Zhang L and Zhao H: Predictive value of high preoperative serum
total protein and elevated hematocrit in patients with
non-small-cell lung cancer after radical resection. Nutr Cancer.
74:3533–3545. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yao Y, Wang Z, Yong L, Yao Q, Tian X, Wang
T, Yang Q, Hao C and Zhou T: Longitudinal and time-to-event
modeling for prognostic implications of radical surgery in
retroperitoneal sarcoma. CPT Pharmacometrics Syst Pharmacol.
11:1170–1182. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abbasi B, Hayat A, Lyons M, Gupta A and
Gupta S: Serum protein and electrolyte imbalances are associated
with chemotherapy induced neutropenia. Heliyon. 8:e099492022.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Iwai N, Okuda T, Sakagami J, Harada T,
Ohara T, Taniguchi M, Sakai H, Oka K, Hara T, Tsuji T, et al:
Neutrophil to lymphocyte ratio predicts prognosis in unresectable
pancreatic cancer. Sci Rep. 10:187582020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Allen J, Cernik C, Bajwa S, Al-Rajabi R,
Saeed A, Baranda J, Williamson S, Sun W and Kasi A: Association of
neutrophil, platelet, and lymphocyte ratios with the prognosis in
unresectable and metastatic pancreatic cancer. J Clin Med.
9:32832020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Terao T, Kumagi T, Hyodo I, Yokota T,
Azemoto N, Miyata H, Kuroda T, Ohno Y, Tanaka Y, Shibata N, et al:
Simple prognostic markers for optimal treatment of patients with
unresectable pancreatic cancer. Medicine (Baltimore).
100:e275912021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shimizu T, Taniguchi K, Asakuma M, Tomioka
A, Inoue Y, Komeda K, Hirokawa F and Uchiyama K:
Lymphocyte-to-monocyte ratio and prognostic nutritional index
predict poor prognosis in patients on chemotherapy for unresectable
pancreatic cancer. Anticancer Res. 39:2169–2176. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kaya T, Acikgoz SB, Yildirim M, Nalbant A,
Altas AE and Cinemre H: Association between
neutrophil-to-lymphocyte ratio and nutritional status in geriatric
patients. J Clin Lab Anal. 33:e226362019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nakamura Y, Imada A, Fukugaki A, Kanto S,
Yamaura T, Kinjo Y and Kuroda N: Association of nutritional risk
and systemic inflammation with survival in patients with colorectal
cancer who underwent curative surgery. Clin Nutr ESPEN. 49:417–424.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Santarpia L, Contaldo F and Pasanisi F:
Nutritional screening and early treatment of malnutrition in cancer
patients. J Cachexia Sarcopenia Muscle. 2:27–35. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Murry DJ, Riva L and Poplack DG: Impact of
nutrition on pharmacokinetics of anti-neoplastic agents. Int J
Cancer. (Suppl 11):48–51. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ikuta S, Sonoda T, Aihara T, Nakajima T
and Yamanaka N: The preoperative modified Glasgow prognostic score
for the prediction of survival after pancreatic cancer resection
following non-surgical treatment of an initially unresectable
disease. Contemp Oncol (Pozn). 22:229–235. 2018.PubMed/NCBI
|
|
36
|
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin
C and Flavell RA: Inflammation-induced cancer: Crosstalk between
tumours, immune cells and microorganisms. Nat Rev Cancer.
13:759–771. 2013. View
Article : Google Scholar : PubMed/NCBI
|
